Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing chronic obstructive pulmonary disease (COPD) in primary care patients with evidence of COPD who either initiate inhaled corticosteroid (ICS) therapy, or have an increase in their ICS dose, as hydrofluoroalkane (HFA) beclometasone dipropionate (BDP) (hereafter Qvar®), CFC-BDP (hereafter BDP) and fluticasone propionate (FP) via pressurised metered-dose inhalers.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Research in Real-Life Ltd
• Collaborators: Teva Branded Pharmaceutical Products R&D, Inc.; Teva Pharmaceutical Industries
• Treatments: Beclomethasone; Fluticasone; Xhance

Criteria

Inclusion Criteria:

• Aged ≥40 years at index prescription date

• COPD diagnosis:

• diagnostic code, and

• ≥2 prescriptions for COPD therapy in baseline year (at different points in time)

• For the ICS increase cohort (i.e. IPDA) ≥1 of these prescriptions must be for ICS therapy.

• Commence ICS therapy at any time (even if before COPD diagnosis is made)

Exclusion Criteria:

• A diagnostic read code for any other chronic respiratory disease (except asthma)